Navigation Links
Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms
Date:3/29/2009

NATICK, Mass. and ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials. SPIRIT II and SPIRIT III are prospective, randomized, non-inferiority trials with 300 and 1,002 patients respectively, designed to compare the safety and efficacy of the PROMUS(R) (XIENCE V(TM)) Everolimus-Eluting Coronary Stent to Boston Scientific's first-generation TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent. SPIRIT II three-year results were presented by Patrick W. Serruys, M.D., Ph.D, and the two-year meta-analysis was presented by Yoshinobu Onuma, M.D., at the 58th Annual Scientific Session of the American College of Cardiology.

The two-year pooled meta-analysis was intended to estimate the incidence of low frequency events or outcomes in key subgroups, and included 892 patients randomized to the PROMUS (XIENCE V) Stent and 410 patients treated with the TAXUS Stent. While overall pooled results and some subgroups at two years favored the PROMUS (XIENCE V) Stent for rates of Major Adverse Cardiac Events (MACE), the MACE results in patients with diabetes favored the TAXUS Stent.

"Clinical data presented at ACC continue to reinforce the value of Boston Scientific's two-drug portfolio," said Keith D. Dawkins, M.D., Associate Chief Medical Officer of Boston Scientific. "While the PROMUS (XIENCE V) Stent performed well against the TAXUS Stent in the meta-analysis, it is important to note that 96 percent of the control patients received the TAXUS Express Stent, making the comparison almost entirely based on our first-generation technology. Of particular interest is the subgroup data on diabetics given the recent discussion in scientific journal
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
3. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
4. RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009
5. Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
6. Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients
7. Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
8. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
9. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. Another LNA-based RNA Inhibitor Enters Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... England and PITTSBURGH ... MYL ) today announced that its shareholders ... plc (NYSE: PRGO ; TASE) and the ... shareholders at an extraordinary general meeting of shareholders ... the votes cast at the extraordinary general meeting. ...
(Date:8/28/2015)... ANDOVER, Massachusetts y LONDRES, 28 de ... PHG, AEX: PHIA) anunció hoy su participación en ... donde exhibirá sus soluciones cardiológicas más recientes y ... IntelliSpace Cardiovascular, que conectan a las personas y ... forma de ayudar a diagnosticar, guiar los tratamientos ...
(Date:8/27/2015)...  The Academy of Managed Care Pharmacy (AMCP) ... draft guidance and proposed rule that calls for ... a nonproprietary name with an FDA-designated suffix. For ... from the FDA on the naming issue and ... the agency to use the same nonproprietary names ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2
(Date:8/30/2015)... (PRWEB) , ... August 31, 2015 , ... Negotiating an ... — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/importholdcrisis , US authorities are ... holding products, and imports from India. , With alerts on an uptick and a ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... announce that Partner Daniel M. Kotin was recently elected to membership in the ... the highest degree of peer recognition and outstanding professionalism. , ABOTA is ...
(Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ( http://www.inhealthmedia.com ... Global Communications Director for InHealth Media. Mr. Spector comes with a wide ... years doing on-air television, producing shows, on air-radio and media relations. , ...
(Date:8/30/2015)... ... August 30, 2015 , ... Nutritional ... from Administrative assistant to Executive Assistant to CEO Mitch Gould for Nutritional Products ... focused on your goals. Kathleen graduated from Florida State University with a ...
(Date:8/29/2015)... ... August 30, 2015 , ... ... — 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple ... digital handwritten signature. , Clinical trial sites can now use audio, ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 2Health News:FDAnews Announces — Negotiating an FDA Import Hold Crisis: Strategies for Challenging FDA Findings Webinar, Sept. 22, 2015 3Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3Health News:InHealth Media Appoints New Global Communications Director 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4
... getting some extra sleep before a big game could ... ,Researcher Cheri Mah and colleagues at Stanford University observed ... ,They were told to maintain their usual sleeping habits ... they were instructed to get as much extra sleep ...
... single act of unprotected sex with an infected partner, adolescent ... chance of getting genital herpes . ,Britain is facing ... in sexually transmitted infections (STIs) and high levels of teenage ... doubt" alcohol and drugs enhance sexual activity, Independent Advisory Group ...
... India is still humming and hawing over the legislation aimed ... and in education. ,Union Health Minister Anbumani ... the Government was still holding talks with the NGOs on ... to the millions of infected. ,The bill ...
... Researchers at the Salk Institute for Biological Studies have found ... kind humans experience in everyday life, may contribute to ... a hallmark of Alzheimers disease. ,The researchers say ... Alzheimers disease, a number of studies have pointed to stress ...
... of HIV have been identified by Yale School of ... genome sequencing technology that quickly detects rare viral mutations. ... and senior author of the retrospective study that used ... today at the 16th International HIV Drug Resistance Workshop ...
... patients with rheumatoid arthritis (RA) is significantly reduced during ... trimester to the third trimester of the participants pregnancy ... ,This is the first prospective study to ... female RA patients throughout their pregnancy and at 6, ...
Cached Medicine News:Health News:UK Facing Major Sexual Health Crisis Among Teens 2Health News:UK Facing Major Sexual Health Crisis Among Teens 3Health News:Bill on HIV/AIDS Delayed Further 2Health News:Emotional Stress Could Be a Factor in Causing Alzheimers: Study 2Health News:HIV Drug Resistance can Be Identified by Genome Sequencing 2Health News:Intensity of Rheumatoid Arthritis Significantly Reduced by Pregnancy 2
B-Hemoglobin test system provide quick, simple and reliable quantitative hemoglobin results. It has unbreakable, disposable cuvette which collect the exact amount of blood and mixes the sample with t...
... System: The D-10 Hemoglobin Testing System ... It provides a fully automated system which ... a single platform. Programs for rapid HbA1c ... away and can be easily integrated into ...
... The ADVIA 120 Hematology System gets ... right the first time, with a ... systems. Results are more accurate, physicians ... more effective. The ADVIA 120 Hematology ...
... The Sysmex XE-2100 provides users with the ... for advanced patient diagnosis and therapeutic monitoring. ... cytometry and advanced cell-counting methods, the XE-2100 ... differential that includes automatic enumeration of NRBC, ...
Medicine Products: